What are the responsibilities and job description for the Senior Director, Market Research position at DBV Technologies?
Description
The Senior Director, Market Research will lead lead strategic insight generation activities to support the Viaskin Peanut Patch launch. This highly-visible role will be critical to ensuring a successful introduction of Viaskin
peanut patch to Healthcare Providers, parents of children with peanut allergy and payers. The Senior Director, Market Research will anticipate information needs, deliver insights with speed and precision, and serve as a trusted advisor during critical decision points.
Location
: Warren, NJ -3 days on site & 2 days remote
Salary Range
:
Key Responsibilities
- Design and oversee comprehensive market research plan, using a range of standard and innovative methodologies and tools, to support a successful launch.
- Identify actionable insights by translating complex data into clear, impactful recommendations to optimize VIASKIN Peanut product positioning, customer segmentation strategies, patient support programs, and promotional effectiveness across HCPs, parents, and payers.
- Establish launch performance metrics and systems to monitor key launch performance indicators
- Conduct rapid-cycle research to optimize the promotional effectiveness of launch tactics; drive course corrections and capitalizations on emerging opportunities
- Build strong relationships across the launch team including brand leadership, sales operations, market access, and field leadership.
- Manage vendor partnerships and internal resources to execute at launch pace
Qualifications
- Bachelor's degree required; advanced degree in business, life sciences, or a related field strongly preferred.
- 10 years of experience in analytics, market research, or commercial insights, preferably within pharma or biotech.
- Proven launch experience in pharma/biotech, with food allergy or immunology experience strongly preferred.
- Demonstrated expertise in leading quantitative and qualitative market research and advanced analytics.
- Extensive experience with launch-focused research methodologies, including pre-launch studies, launch tracking, promotional optimization, and early performance analytics.
- Strong ability to translate complex data into clear, concise insights that inform strategic decision-making.
- Confident leadership presence with a strong sense of accountability in delivering recommendations to senior and executive stakeholders.
- Ability to operate with urgency while maintaining high-quality standards, fostering transparency, alignment, and effective cross-functional collaboration.
Behavioral Skills
- Curiosity: Continuously explore new approaches and ask the right questions to uncover unmet needs and opportunities.
- Courage: Take thoughtful risks, challenge assumptions, and advocate for evidence-based choices that improve outcomes.
- Collaboration: Foster teamwork across functions, share knowledge, and support collective achievement of strategic goals.
- Credibility: Build trust through transparency, rigorous methods, and dependable delivery of insights that drive impact.
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively.
We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin, to develop treatment options for immunologic diseases with significant unmet medical need.
This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin.
Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy.
Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.